Hrt Financial LP Galectin Therapeutics Inc Transaction History

Hrt Financial LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$1.19 - $1.74 $17,632 - $25,781	14,817 New	14,817 $19,000
Q4 2021 Feb 14, 2022	SELL	$2.07 - $3.8 $166,047 - $304,820	-80,216 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$2.59 - $4.15 $64,050 - $102,629	-24,730 Reduced 23.56%	80,216 $311,000
Q2 2021 Aug 16, 2021	BUY	$2.07 - $5.1 $217,238 - $535,224	104,946 New	104,946 $335,000
Q4 2018 Feb 15, 2019	SELL	$3.43 - $5.74 $51,621 - $86,387	-15,050 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$3.68 - $6.93 $55,384 - $104,296	15,050 New	15,050 $90,000

9.65M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.